Premium
Incidence and mortality rates of Guillain‐Barré syndrome in Serbia
Author(s) -
Stojanov Aleksandar,
Berisavac Ivana,
Bozovic Ivo,
Arsenijevic Mirjana,
LukicRajic Sonja,
Petrovic Milutin,
StojiljkovicTamas Olivera,
Jovin Zita,
Djordjevic Gordana,
Jovanovic Dejana,
Stojanovic Miroslav,
Martic Vesna,
Basta Ivana,
Peric Stojan
Publication year - 2020
Publication title -
journal of the peripheral nervous system
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1
H-Index - 67
eISSN - 1529-8027
pISSN - 1085-9489
DOI - 10.1111/jns.12412
Subject(s) - incidence (geometry) , medicine , guillain barre syndrome , polyradiculoneuropathy , pediatrics , epidemiology , confidence interval , mortality rate , physics , optics
Abstract Guillain‐Barré syndrome (GBS) is an acute auto‐immune polyradiculoneuropathy. A huge variety of GBS incidence and mortality rates has been noted across the world. The objective of the present multi‐centric study was to assess the incidence and mortality rates of GBS during a 10‐year period in Serbia. We collected data of adult GBS patients who were hospitalized from 2009 to 2018 in all five tertiary healthcare centers in Serbia. The incidence rates per 100 000 inhabitants with 95% confidence intervals (CI) were calculated and further corrected for the estimated number of patients hospitalized in secondary centers. Mortality rates were also assessed. GBS was considered severe if patients were not able to walk at least 10 m without assistance. Six hundred and forty GBS patients were registered in tertiary centers in a 10‐year period. The proportion of severe cases was 75% at nadir, and 52% on discharge. GBS incidence rate in Serbia was 1.1 per 100 000 inhabitants, and estimated incidence if patients from secondary centers included 1.2 per 100 000. Peak incidence was observed during the sixth decade of life. During the acute phase, 5.6% of GBS patients died, while overall 9.7% of them died during 6‐month period from disease onset. This study contributes to our knowledge about GBS epidemiology. Results will allow us to improve the diagnosis and treatment of GBS patients in Serbia.